Professor Gail Risbridger
Position:
- Deputy Dean, Strategic Projects, Faculty Medicine Nursing & Health Science, Monash University
- Research Director, Monash Comprehensive Cancer Consortium
- Head, Prostate Cancer Research Program, Department Anatomy & Developmental Biology, Monash University
- Fellow, National Health and Medical Research Council
Websites:
Biography:
Professor Gail Risbridger is an NH&MRC Research Fellow, career academic and researcher who has >25 years’ experience in Prostate Cancer research and Men’s Health. She graduated from, and taught at Monash University, until becoming a founding member of the Monash Institute of Medical Research (MIMR) now known as the Hudson Institute of Medical Research. Currently, she heads the Prostate Cancer Research Group in the Department of Anatomy & Developmental Biology at Monash University, leading an internationally recognised research team of scientists and clinicians working on prostate cancer and Andrology related projects. She is one of Australia’s leading prostate cancer researchers and pioneered the use of stem cells for recombination studies combining stem cell biology with endocrinology.
Prof Risbridger holds the positions of Deputy Dean, Strategic Projects, Research Director of Monash Comprehensive Cancer Consortium (MCCC) and Chair, Faculty Research Centres & Institutes Committee in the Faculty of Medicine Nursing & Health Sciences, Monash University as well as advisory roles in Andrology Australia and the Freemasons Foundation Centre for Men’s Health.
Her academic and industry collaborations have built infrastructure and trained some of the workforce required to underpin the national research effort in Australian Prostate Cancer Research, including a National tissue bank with Victorian State Government informatics support. She has authored over >215 publications, and has received more than $23M in National and International grant funding since 2003. Her awards include an International Fulbright Senior Scholar Award, British Endocrine Society Asia-Oceania Medal and Honorary Life Member of Endocrine Society of Australia.
Best publications:
- Risbridger GP, Taylor RA, Clouston D, Sliwinski A, Thorne H, Hunter S, Li J, Mitchell G, Murphy D, Frydenberg M, Pook D, Pedersen J, Toivanen R, Wang H, Papargiris M, Lawrence MG, Bolton DM. (2015) Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. European Urology. Mar;67(3):496-503
- Toivanen R, Frydenberg M, Murphy D, Pedersen J, Ryan A, Pook D, Berman DM, Australian Prostate Cancer BioResource, Taylor RA, Risbridger GP (2013). A pre-clinical model to identify castrate-resistant cancer repopulating cells in localized prostate tumors. Science Translational Medicine 5(187):187ra71
- Clark AK, Taubenberger AV, Taylor RA, Niranjan B, Chea ZY, Zotenko E, Sieh S, Pedersen J, Norden S, Frydenberg M, Grummet J, Pook DW, Australian Prostate Cancer BioResourse, Stirzaker C, Clark SJ, Lawrence MG, Ellem SJ, Hutmacher DW, Risbridger GP (2013). A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer. Biomaterials 34(20):4777-4785
- MG. Lawrence, RA. Taylor, R Toivanen, J Pedersen, S Norden, D W. Pook, M Frydenberg, Australian Prostate Cancer BioResource, MM. Papargiris, B Niranjan, MG. Richards, H Wang, AT. Collins, NJ. Maitland, GP. Risbridger (2013). A preclinical xenograft model of prostate cancer using human tumours. Nature Protocols 8(5):836-48
- Risbridger GP, Davis ID, Birrell S, Tilley WD (2010). Breast and prostate cancer: more similar than different. Nature Reviews Cancer 10(3):205-212
